These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34262299)

  • 1. Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study.
    Hozawa S; Ohbayashi H; Tsuchiya M; Hara Y; Lee LA; Nakayama T; Tamaoki J; Fowler A; Nishi T
    J Asthma Allergy; 2021; 14():809-819. PubMed ID: 34262299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S; Lee LA; Sule N; Fowler A; Peachey G
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan.
    Umeda A; Shimada H; Yamane T; Mochizuki T; Inoue Y; Tsushima K; Miyagawa K; Mochida A; Takeda H; Okada Y; Masaki K; Matsusaka M; Fukunaga K
    Front Physiol; 2023; 14():1131949. PubMed ID: 37179838
    [No Abstract]   [Full Text] [Related]  

  • 8. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
    Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
    Respir Investig; 2024 Jul; 62(4):685-694. PubMed ID: 38796907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
    Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
    Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
    Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.
    Busse WW; Abbott CB; Germain G; Laliberté F; MacKnight SD; Jung Y; Duh MS; Averell CM
    J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2904-2913.e6. PubMed ID: 35752431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
    Bourdin A; Criner G; Devouassoux G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kalhan R; Lange P; Lettis S; Lipson DA; Lomas DA; Echave-Sustaeta María-Tomé JM; Martin N; Martinez FJ; Quasny H; Sail L; Siler TM; Singh D; Thomashow B; Watz H; Wise R; Hanania NA
    Chronic Obstr Pulm Dis; 2021 Jan; 8(1):76-90. PubMed ID: 33156982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
    Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.